Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia

 Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia

Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia

Shots:

  • The P-III study involves assessing of Evinacumab vs PBO in patients with homozygous familial hypercholesterolemia (HoFH) for 24wks.
  • The P-III study results: reduction in LDL cholesterol (49% vs 47%); LDL cholesterol levels<100mg/dL (47% vs 23%); similar reduction in LDL cholesterol level in “negative/negative” patients; reduction in apolipoprotein B (ApoB), non-HDL cholesterol and total cholesterol; AEs (66% vs 81%)
  • Evinacumab is an investigational mAb targeting ANGPTL3, currently being evaluated in P-III study for HoFH and P-II studies for refractory hypercholesterolemia and severe hypertriglyceridemia and has received the US FDA’s BT designation for the treatment of hypercholesterolemia in patients with HoFH in 2017

Click here to­ read full press release/ article | Ref: Regeneron | Image: High Point University

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post